Literature DB >> 15109359

Inpatient treatment of headache: an evidence-based assessment.

Frederick G Freitag1, Al Lake, Richard Lipton, Roger Cady, Seymour Diamond, Stephen Silberstein.   

Abstract

OBJECTIVE: To evaluate inpatient treatment of headache in the United States. PARTICIPANTS: Participants were selected by the meeting chairpersons, Drs. Diamond and Silberstein as well as Dr. Freitag. Criteria for selection included participation in an inpatient treatment program, headache specialists not affiliated with an inpatient treatment program, clinician with interest in headache but not affiliated with a dedicated headache treatment program. The single meeting held in New York was by invitation only. All invitees were provided with opportunity to present their views and participate in the recommendations of the Consortium. The list of participants at the meeting were: Harvey Blumenthal, MD, Roger Cady, MD, James Couch, MD, Seymour Diamond, MD, Frederick G. Freitag, DO, R. Michael Gallagher, DO, Al Lake III, PhD, Richard Lipton, MD, NinanMathew,MD, Alan Rapoport, MD, Jay Rosenberg, MD, Joel Saper, MD, Stephen Silberstein, MD. Funding for theproject was provided by the US Headache Guidelines Consortium Project through the American Academy of Neurology and the National Headache Foundation. EVIDENCE: Each of the authors were part of the writing committee each with specific areas that they were responsible for conducting the literature reviews and submitting a portion of the original document for editing and review. Dr. Freitag coordinated this process and assembled the first draft of the article for circulation and review among the authors and chairpersons. In the absence of class I evidence consensus expert opinion was fundamental to the process.
CONCLUSIONS: The treatment of headache is commonly delivered in the outpatient office environment. There exists a group of patients who have been refractive to outpatient treatment and in whom in patient care may be appropriate. The factors that determine the optimal treatment setting, the methodology of the treatment and the results of such treatment have come under increasing scrutiny secondary to the cost of treatment in the hospital. The US Headache Consortium guidelines project in conjunction with the national headache foundation believed that the need existed to objectively examine the issues surrounding inpatient treatment. The epidemiology of chronic headache is important to understand in this context since essentially all patients that are treated in hospital have high frequency headache often associated with significant disability. This severity of illness produces both health care costs but also is responsible for significant impact on businesses and the economy. The method of treatment of headache in the hospital environment can follow several paths based on the accessibility of the resources specific to headache treatment. While there exist these differing paths of treatment only treatment in a dedicated headache treatment unit has been investigated in depth here in the US though reports from other countries that do not have dedicated inpatient treatment lends support to options in headache treatment. Some have suggested that inpatient treatment is not required even in recidivist patients and limited reports have examined aggressive outpatient treatment as an option in headache management. None of the studies reported to date provide class one evidence for efficacy either inpatient or outpatient. Recommendations are made to assess headache treatment in patients with high frequency headaches to garner better scientific evidence for differing treatment approaches.

Entities:  

Mesh:

Year:  2004        PMID: 15109359     DOI: 10.1111/j.1526-4610.2004.04093.x

Source DB:  PubMed          Journal:  Headache        ISSN: 0017-8748            Impact factor:   5.887


  14 in total

1.  Transcutaneous supraorbital neurostimulation for the prevention of chronic migraine: a prospective, open-label preliminary trial.

Authors:  Paola Di Fiore; Gennaro Bussone; Alberto Galli; Henri Didier; Cesare Peccarisi; Domenico D'Amico; Fabio Frediani
Journal:  Neurol Sci       Date:  2017-05       Impact factor: 3.307

Review 2.  Inpatient management of migraine.

Authors:  Michael J Marmura; Stephanie Wrobel Goldberg
Journal:  Curr Neurol Neurosci Rep       Date:  2015-04       Impact factor: 5.081

Review 3.  Behavioral medicine for migraine and medication overuse headache.

Authors:  Frank Andrasik; Dawn C Buse; Licia Grazzi
Journal:  Curr Pain Headache Rep       Date:  2009-06

4.  The pharmacological management of migraine, part 1: overview and abortive therapy.

Authors:  George Demaagd
Journal:  P T       Date:  2008-07

Review 5.  Headache with medication overuse: treatment strategies and proposals of relapse prevention.

Authors:  Licia Grazzi; Frank Andrasik; Susanna Usai; Gennaro Bussone
Journal:  Neurol Sci       Date:  2008-05-16       Impact factor: 3.307

Review 6.  When should "chronic migraine" patients be considered "refractory" to pharmacological prophylaxis?

Authors:  Domenico D'Amico; Massimo Leone; Licia Grazzi; Gennaro Bussone
Journal:  Neurol Sci       Date:  2008-05       Impact factor: 3.307

7.  In-patient vs. day-hospital withdrawal treatment for chronic migraine with medication overuse and disability assessment: results at one-year follow-up.

Authors:  Licia Grazzi; Frank Andrasik; Susanna Usai; Gennaro Bussone
Journal:  Neurol Sci       Date:  2008-05       Impact factor: 3.307

Review 8.  Chronic daily headache: transformational migraine, chronic migraine, and related disorders.

Authors:  Joel R Saper
Journal:  Curr Neurol Neurosci Rep       Date:  2008-03       Impact factor: 5.081

Review 9.  Update of Inpatient Treatment for Refractory Chronic Daily Headache.

Authors:  Tzu-Hsien Lai; Shuu-Jiun Wang
Journal:  Curr Pain Headache Rep       Date:  2016-01

10.  Migraine disability, healthcare utilization, and expenditures following treatment in a tertiary headache center.

Authors:  Frederick G Freitag; Heidi Lyss; George R Nissan
Journal:  Proc (Bayl Univ Med Cent)       Date:  2013-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.